Our portfolio of liver diseases has grown again, this time to include hepatitis D. The new HDV entry inhibitor, bulevirtide (Hepcludex®) is now listed on our interactions checker. Bulevirtide is currently licensed in Europe and is expected to be approved by the FDA in 2022.
Bulevirtide has been added to our Overview of Interactions tables. We have also uploaded a new PK Fact Sheet about bulevirtide.
